Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection
about
Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytesThe current status and future directions of hepatitis B antiviral drug discovery.New antivirals for the treatment of chronic hepatitis B.Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.Investigational drugs in development for Hepatitis D.Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification.Genetic Diversity and Worldwide Distribution of the Deltavirus Genus: a Study of 2,152 Clinical Strains.Hepatitis delta virus infection in a large cohort of chronic hepatitis B patients in Ethiopia.Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.Nucleic acid polymers are active against Hepatitis Delta Virus infection in vitro.Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds.Activity of nucleic acid polymers in rodent models of HBV infection.Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo.Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?
P2860
Q33821878-4C8FCE0F-3440-4EA2-9D49-29D199F780BBQ38802098-CF34E9F2-865F-47EF-A90C-3B6EDCAC6627Q39315990-62F5584E-9CA5-49B2-A7A2-50FB26CB9A96Q39414876-1D1A6B91-A9B7-4607-B440-9957234206ADQ40113645-19096341-470B-41C3-BE55-B14DE902A544Q40302798-FA9BE8F5-E734-4A4B-B0B5-6C67FE0477F1Q40437975-366CF0CD-FE14-4924-9F0D-B61B1CA0E6A7Q41921473-0A3BAD01-C4B9-46CC-90AB-35ADE1B73AC6Q41923818-379DB483-7984-40CE-AD54-0538132DFA91Q42209643-5F9B8F48-A5A6-44B1-8016-2DCE3A33375BQ45323707-A4B64AF9-19AC-4FCF-A6FE-20BB32F176AAQ45324711-8982B33B-5399-4046-800A-F0A96CB9D838Q46263692-7C2C0469-031C-4F05-A0AA-043D1080F4C5Q47564306-70432A4C-03EB-4AE2-841A-BA6C93C45756Q52431500-681D978F-6AA8-41A6-B55F-030151F85960
P2860
Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@ast
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@en
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@nl
type
label
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@ast
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@en
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@nl
prefLabel
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@ast
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@en
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@nl
P1433
P1476
Nucleic acid polymers: Broad s ...... is B and hepatitis D infection
@en
P2093
Andrew Vaillant
P356
10.1016/J.ANTIVIRAL.2016.07.004
P577
2016-07-09T00:00:00Z